Search
Dexniguldipine
go.drugbank.com/drugs/DB14068ExperimentalCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesHydrocortisone acetate
go.drugbank.com/drugs/DB14539ApprovedInvestigationalVet approvedCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InducersHydrocortisone valerate
go.drugbank.com/drugs/DB14544ApprovedVet approvedCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InducersEdetate disodium anhydrous
go.drugbank.com/drugs/DB14600ApprovedInvestigationalVet approvedEdetate disodium anhydrous is a polyvalent chelating agent used to treat hypercalcemia and digitalis toxicity associated ventricular arrhythmias.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsPrednisolone phosphate
go.drugbank.com/drugs/DB14631ApprovedInvestigationalVet approvedPrednisolone phosphate is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone phosphate was granted FDA Approval on 19 December 1973.
Categories: P-glycoprotein inducers, Cytochrome P-450 CYP2A6 InducersLarotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigationalLarotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesFilgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigationalRheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. The disease is associated with extra-articular manifestations, prog...
Categories: P-glycoprotein substratesOliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigational[A218026, A218031, A218036, A218041, A218046] Oliceridine (formerly known as TRV130) is a "biased agonist" at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor … [A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesMavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalMavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is ...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesUmbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawnMarginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with rituximab (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse o...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates